# Bionomics Limited (BNOX)

Source: https://www.quantisnow.com/company/BNOX
Generated: 2026-11-17T13:53:14.557Z

- Ticker: BNOX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: https://www.bionomics.com.au

## About

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

## Latest BNOX news and filings

- 2025-01-07 11:18 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by Bionomics Limited](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-bionomics-limited-5836577)
- 2024-12-30 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-effect-filed-by-bionomics-limited-5826358)
- 2024-12-30 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-effect-filed-by-bionomics-limited-5826348)
- 2024-12-23 22:14 UTC [SEC Form 8-K] [Bionomics Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Changes in Control of Registrant, Leadership Update, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionomics-limited-filed-sec-form-8-k-entry-into-a-material-5824224)
- 2024-12-23 22:03 UTC [SEC Form POS AM filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-bionomics-limited-5824191)
- 2024-12-23 22:02 UTC [SEC Form POS AM filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-bionomics-limited-5824180)
- 2024-12-23 21:56 UTC [SEC Form 15-12G filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-bionomics-limited-5824133)
- 2024-12-16 21:46 UTC [SEC Form 8-K] [Bionomics Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionomics-limited-filed-sec-form-8-k-other-events-financial-statements-5815215)
- 2024-12-16 21:05 UTC [Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation](https://www.quantisnow.com/insight/bionomics-announces-supreme-court-of-new-south-wales-approves-bionomics-5814733)
- 2024-12-12 22:02 UTC [SEC Form 8-K] [Bionomics Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionomics-limited-filed-sec-form-8-k-submission-of-matters-to-5811665)
- 2024-12-12 21:05 UTC [Results of Scheme Meeting](https://www.quantisnow.com/insight/results-of-scheme-meeting-5811122)
- 2024-12-09 13:00 UTC [Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence](https://www.quantisnow.com/insight/bionomics-publishes-the-positive-results-from-the-phase-2-attune-5804732)
- 2024-12-03 21:05 UTC [Conference Announcement] [Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting](https://www.quantisnow.com/insight/bionomics-to-present-at-the-2024-american-college-of-neuropsychopharmacology-5797928)
- 2024-12-02 22:01 UTC [Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States](https://www.quantisnow.com/insight/bionomics-reminds-shareholders-to-cast-their-vote-for-re-domiciliation-from-5796372)
- 2024-11-25 21:33 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by Bionomics Limited](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-bionomics-limited-5790423)
- 2024-11-21 21:01 UTC [SEC Form 8-K] [Bionomics Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionomics-limited-filed-sec-form-8-k-entry-into-a-material-5786620)
- 2024-11-18 21:41 UTC [SEC Form S-3] [SEC Form S-3 filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-bionomics-limited-5781022)
- 2024-11-14 21:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bionomics-limited-5775675)
- 2024-11-14 20:25 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-bionomics-limited-5775099)
- 2024-11-14 14:03 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Bionomics Limited](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-bionomics-limited-5773670)
- 2024-11-13 21:55 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-bionomics-limited-5772076)
- 2024-11-12 21:06 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-bionomics-limited-5767524)
- 2024-11-08 21:30 UTC [SEC Form 8-K] [Bionomics Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionomics-limited-filed-sec-form-8-k-other-events-financial-statements-5762887)
- 2024-11-08 21:15 UTC [Public Offering] [Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement](https://www.quantisnow.com/insight/bionomics-provides-an-update-on-re-domiciliation-via-scheme-of-arrangement-5762624)
- 2024-11-07 13:00 UTC [Conference Announcement] [Bionomics to Present at the 2024 CNS Summit](https://www.quantisnow.com/insight/bionomics-to-present-at-the-2024-cns-summit-5757746)
- 2024-11-04 21:15 UTC [Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program](https://www.quantisnow.com/insight/bionomics-receives-milestone-payment-of-aus1m-from-carina-biotech-for-5750978)
- 2024-10-23 10:00 UTC [Conference Announcement] [Bionomics to Present at the ThinkEquity Conference](https://www.quantisnow.com/insight/bionomics-to-present-at-the-thinkequity-conference-5734180)
- 2024-10-14 12:00 UTC [Conference Announcement] [Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC](https://www.quantisnow.com/insight/bionomics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-5724044)
- 2024-10-10 21:00 UTC [SEC Form 8-K] [Bionomics Limited filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/bionomics-limited-filed-sec-form-8-k-leadership-update-5722658)
- 2024-10-09 12:47 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-bionomics-limited-5720675)
- 2024-10-07 22:10 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Bionomics Limited](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-bionomics-limited-5718720)
- 2024-10-07 12:00 UTC [Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision](https://www.quantisnow.com/insight/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision-5717854)
- 2024-10-01 10:30 UTC [Bionomics Limited announces intention to re-domicile to the United States](https://www.quantisnow.com/insight/bionomics-limited-announces-intention-to-re-domicile-to-the-united-states-5709212)
- 2024-09-30 10:38 UTC [SEC Form 10-K] [SEC Form 10-K filed by Bionomics Limited](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-bionomics-limited-5707665)
- 2024-09-03 10:30 UTC [Conference Announcement] [Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference](https://www.quantisnow.com/insight/bionomics-to-present-at-the-hc-wainwright-26th-annual-global-5678759)
- 2024-07-31 10:30 UTC [Earnings Date] [Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder](https://www.quantisnow.com/insight/bionomics-announces-successful-end-of-phase-2-meeting-with-the-fda-on-5634253)
- 2024-07-29 20:30 UTC [Earnings Date] [Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024](https://www.quantisnow.com/insight/bionomics-to-provide-a-corporate-update-and-discuss-end-of-phase-2-5631509)
- 2024-07-18 16:43 UTC [Market Chatter] [HC Wainwright & Co. Reiterates Buy on Bionomics, Maintains $8 Price Target](https://www.quantisnow.com/insight/hc-wainwright-co-reiterates-buy-on-bionomics-maintains-8-price-5615422)
- 2024-07-18 10:47 UTC [Market Chatter] [Bionomics Has Initiated Patient Screening For The Phase 3 AFFIRM-1 Trial Evaluating The Safety And Efficacy Of BNC210 For The Acute, As-needed Treatment Of Social Anxiety Disorder, Topline Results Are Expected In Q3 2025](https://www.quantisnow.com/insight/bionomics-has-initiated-patient-screening-for-the-phase-3-affirm-1-5614351)
- 2024-07-18 10:30 UTC [Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder](https://www.quantisnow.com/insight/bionomics-initiates-affirm-1-a-phase-3-clinical-trial-with-bnc210-5614304)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BNOX
- Earnings history: https://www.quantisnow.com/earnings/BNOX
- Dividend history: https://www.quantisnow.com/dividends/BNOX
- Insider transactions: https://www.quantisnow.com/insiders/BNOX
- Options chain: https://www.quantisnow.com/options/BNOX
- SEC 8-K filings only: https://www.quantisnow.com/company/BNOX/8-k
- RSS and alerts for BNOX: https://www.quantisnow.com/docs/rss-feeds.md
